Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial
Sponsor: National Cancer Institute (NCI)
This observational or N/A phase trial investigates Cancer and Death and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 70 recorded versions since 1998 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Study Description(click to expand)The Division of Cancer Preventionl (DCP, formerly DCPC), under extramural contracts to 10 U.S. clinical centers, is evaluating the effectiveness of screening for prostate, lung, colorectal and ovarian cancer (The PLCO Trial). In 1996 the NCI Executive Committee approved the expansion of the PLCO Trial to collect additional materials and to conduct additional studies. About, 74,000 men and 74,000 women, aged 55-74 years, have been randomized on a 50/50 basis into screening or usual care arms. Additional blood is collected from screened subjects and saliva for buccal cells from control subjects. Pathologic tissues are obtained for selected cases that develop cancer or selected related diseases (e.g. colon polyps, benign prostatic hyperplasia). Additional questionnaire-based risk and disease-related information is also collected, with confirmation of disease status from medical records. Genetic, biochemical and questionnaire-based risk information will be related to the development of cancer and other diseases in this population. Volunteers who provide samples for these studies will not routinely receive their individual results from the Additional Investigation. Subjects requesting such information, however, will be provided their test results. In 2009 the NCI Executive Committee approved the Extended Follow-up of subjects beyond the original 13-year follow-up period. Participants will be reconsented for...
The Division of Cancer Preventionl (DCP, formerly DCPC), under extramural contracts to 10 U.S. clinical centers, is evaluating the effectiveness of screening for prostate, lung, colorectal and ovarian cancer (The PLCO Trial). In 1996 the NCI Executive Committee approved the expansion of the PLCO Trial to collect additional materials and to conduct additional studies. About, 74,000 men and 74,000 women, aged 55-74 years, have been randomized on a 50/50 basis into screening or usual care arms. Additional blood is collected from screened subjects and saliva for buccal cells from control subjects. Pathologic tissues are obtained for selected cases that develop cancer or selected related diseases (e.g. colon polyps, benign prostatic hyperplasia). Additional questionnaire-based risk and disease-related information is also collected, with confirmation of disease status from medical records. Genetic, biochemical and questionnaire-based risk information will be related to the development of cancer and other diseases in this population. Volunteers who provide samples for these studies will not routinely receive their individual results from the Additional Investigation. Subjects requesting such information, however, will be provided their test results. In 2009 the NCI Executive Committee approved the Extended Follow-up of subjects beyond the original 13-year follow-up period. Participants will be reconsented for the release of records to a single NCI-Designated Central Data Collection Center (CDCC), which will administer the annual mailings containing the annual study update questionnaire and a brief (1-2 page) risk factor questionnaire. Individuals who do not consent to release their identifiers to the CDCC will be followed up passively through linkage to state cancer registries and the National Death Index.
This protocol Review Application is for (1) the collaboration of intramural scientists in the Division of Cancer Epidemiology and Genetics (DCEG) in the Additional Studies and (2) the coordination, in collaboration with DCP, of the Extended Follow-up.
Status Flow
Change History
70 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
-
Mar 2026 — May 2026 [monthly]
Active Not Recruiting
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting
-
Jul 2025 — Jan 2026 [monthly]
Active Not Recruiting
▶ Show 65 earlier versions
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting
-
Oct 2024 — Dec 2024 [monthly]
Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting
-
Apr 2023 — Jun 2023 [monthly]
Active Not Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting
-
Nov 2022 — Jan 2023 [monthly]
Active Not Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting
-
May 2022 — Jun 2022 [monthly]
Active Not Recruiting
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting
-
Feb 2022 — Apr 2022 [monthly]
Active Not Recruiting
-
Dec 2021 — Feb 2022 [monthly]
Active Not Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Active Not Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Active Not Recruiting
-
May 2021 — Oct 2021 [monthly]
Active Not Recruiting
-
Apr 2021 — May 2021 [monthly]
Active Not Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Sep 2020 — Dec 2020 [monthly]
Active Not Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Active Not Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Active Not Recruiting
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Active Not Recruiting
-
Feb 2020 — Mar 2020 [monthly]
Active Not Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting
-
Nov 2019 — Jan 2020 [monthly]
Active Not Recruiting
-
Oct 2019 — Nov 2019 [monthly]
Active Not Recruiting
-
Sep 2019 — Oct 2019 [monthly]
Active Not Recruiting
-
Aug 2019 — Sep 2019 [monthly]
Active Not Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting
-
May 2019 — Jun 2019 [monthly]
Active Not Recruiting
-
Nov 2018 — May 2019 [monthly]
Active Not Recruiting
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting
-
Jul 2018 — Sep 2018 [monthly]
Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
First recorded
May 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The Division of Cancer Preventionl (DCP, formerly DCPC), under extramural contracts to 10 U.S. clinical centers, is evaluating the effectiveness of screening for prostate, lung, colorectal and ovarian cancer (The PLCO Trial). In 1996 the NCI Executive Committee approved the expansion of the PLCO Trial to collect additional materials and to conduct additional studies. About, 74,000 men and 74,000 women, aged 55-74 years, have been randomized on a 50/50 basis into screening or usual care arms. Additional blood is collected from screened subjects and saliva for buccal cells from control subjects. Pathologic tissues are obtained for selected cases that develop cancer or selected related diseases (e.g. colon polyps, benign prostatic hyperplasia). Additional questionnaire-based risk and disease-related information is also collected, withconfirmation of disease status from medical records. Genetic, biochemical and questionnairebasedrisk information will be related to the development of cancer and other diseases in this population. Volunteers who provide samples for these studies will not routinely receive their individual results from the Additional Investigation. Subjects requesting such information, however, will be provided their test results. In 2009 the NCI Executive Committee approved the Extended Follow-up of subjects beyond the original 13-year follow-up period. Participants will be reconsented for the release of records to a single NCI-Designated Central Data Collection Center (CDCC), which will administer the annual mailings containing the annual study update questionnaire and a brief (1-2 page) risk factor questionnaire. Individuals who do not consent to release their identifiers to the CDCC will be followed up passively through linkage to state cancer registries and the National Death Index. This protocol Review Application is for (1) the collaboration of intramural scientists in the Division of Cancer Epidemiology and Genetics (DCEG) in the Additional Studies and (2) the coordination, in collaboration with DCP, of the Extended Follow-up....
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .